Saturday 17 October 2026
Export XBIO’s income statement to Excel — free account
Xenetic Biosciences, Inc.
XBIO Healthcare Biotechnology
Xenetic Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.0 million, up 19.0% from fiscal 2024. In the quarter to June 2026, revenue grew 12.0%, EPS grew 8.89% and free cash flow fell 128.1%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
1.98
0.03
−1.49%
Follow XBIO
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
5 | 3 | 4 | 3 | 4 | — | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
Altman Z-Score |
(30.91) | (36.53) | (21.77) | (16.08) | (7.15) | (13.09) | (11.65) | — | (8.58) | (12.46) |
P/S ratio |
1.24 | 2.46 | 2.15 | 2.54 | 11.42 | 29.85 | 0.48 | — | 0.00 | 0.00 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 11.09 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(66.61) | (84.78) | (44.13) | (25.99) | (12.66) | (31.87) | (22.02) | — | (21.64) | (31.76) |
P/Operating CF |
(15.21) | (9.12) | (6.88) | (5.78) | (9.09) | (13.67) | (2.45) | — | 3.40 | (8.67) |
P/B ratio |
0.50 | 1.02 | 0.56 | 0.32 | 0.72 | 1.07 | 0.24 | — | 1.15 | 2.48 |
Price to Tangible BV |
0.00 | 0.00 | 9.91 | 0.99 | 1.45 | 4.39 | 0.52 | — | 9.29 | 11.02 |
EV/Sales |
(1.03) | 0.45 | (0.94) | (4.47) | (3.32) | 6.06 | (0.60) | — | 0.00 | 0.00 |
EV/EBITDA |
1.08 | 0.00 | 0.53 | 1.14 | 0.67 | 0.00 | 0.53 | — | 0.00 | 0.00 |
EV/Operating CF |
1.34 | (0.40) | 0.58 | 1.64 | 0.81 | (0.62) | 0.80 | — | 8.03 | (4.22) |
EV/FCF |
1.34 | (0.40) | 0.58 | 1.64 | 0.81 | (0.62) | 0.80 | — | 8.08 | (4.22) |
Quick Ratio |
8.14 | 6.89 | 11.10 | 12.20 | 12.84 | 12.30 | 7.33 | 0.40 | 2.88 | 3.81 |
Current Ratio |
8.32 | 7.37 | 11.84 | 12.72 | 13.18 | 13.20 | 7.84 | 0.75 | 3.03 | 4.47 |
Net Debt/EBITDA |
2.78 | 1.47 | 1.99 | 1.96 | 3.19 | 0.83 | 1.08 | 0.09 | 1.58 | 0.09 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.39 | 0.29 | 0.20 | 0.10 | 0.07 | 0.03 | 0.00 | 0.00 | 0.38 | 0.16 |
Operating CF/Net income |
0.85 | 0.71 | 1.00 | 0.71 | 0.84 | 0.39 | 0.35 | 0.89 | (0.42) | 0.15 |
Capex/Depreciation |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 1.42 | (0.39) | (0.03) |
Interest Coverage |
— | — | — | (40.18) | (57.18) | (110.44) | (59.39) | (14,552.60) | (216.29) | (65.01) |
| (40.01%) | (50.13%) | (35.28%) | (40.91%) | (36.89%) | (74.05%) | (133.18%) | (60.31%) | (23.60%) | (511.45%) | |
| (35.12%) | (45.24%) | (32.65%) | (37.95%) | (34.22%) | (62.74%) | (100.39%) | (43.46%) | (17.91%) | (307.49%) | |
ROIC |
0.00% | 0.00% | (347.32%) | (763.68%) | (2,389.72%) | (1,266.33%) | (117.66%) | (49.03%) | (25.63%) | (245.91%) |
Return on Tangible Assets |
(37.86%) | (69.56%) | (47.11%) | (52.09%) | (32.63%) | (95.28%) | (186.65%) | 1,821.48% | (90.59%) | (893.94%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 365.00 |
Research and Development Expense of Revenue |
102.99% | 131.52% | 137.59% | 279.50% | 272.55% | 396.29% | 28,592.40% | 0.00% | 53.53% | 1,457.93% |
Selling, General and Administrative Expense of Revenue |
92.24% | 136.64% | 140.19% | 214.07% | 322.56% | 778.23% | 27,667.84% | 0.00% | 91.46% | 223.09% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.43 | 0.87 | 0.65 | 0.60 |
Share Based Compensation of Revenue |
2.18% | 6.87% | 11.15% | 29.97% | 35.36% | 107.32% | 4,991.23% | 0.00% | 23.64% | 70.11% |
Graham Net Nets |
1.92 | 0.93 | 1.61 | 2.90 | 1.30 | 0.87 | 1.65 | — | 0.06 | 0.09 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
Earnings Yield |
(73.27%) | (64.41%) | (77.03%) | (154.10%) | (42.31%) | (82.84%) | (672.30%) | — | (22.64%) | (136.38%) |
Free Cash Flow Yield |
(61.87%) | (45.78%) | (75.37%) | (107.06%) | (35.72%) | (32.71%) | (155.77%) | — | 9.02% | (21.95%) |
Revenue per Share |
1.75 | 1.62 | 1.66 | 1.20 | 1.13 | 0.68 | 0.06 | 0.00 | 105.06 | 48.47 |
Operating CF per Share |
(1.34) | (1.83) | (2.69) | (3.27) | (4.61) | (6.68) | (22.44) | (85.50) | 20.70 | (141.96) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.30 | (0.13) | (0.27) |
Free Cash Flow per Share |
(1.34) | (1.83) | (2.69) | (3.27) | (4.61) | (6.68) | (22.43) | (85.20) | 20.57 | (142.23) |
Cash per Share |
4.63 | 4.00 | 5.88 | 9.21 | 17.75 | 18.03 | 36.35 | 8.44 | 77.56 | 66.47 |
Shareholders Equity per Share |
4.35 | 3.90 | 6.41 | 9.59 | 17.90 | 19.11 | 60.36 | 131.12 | 198.08 | 261.22 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
4.35 | 3.90 | 6.41 | 9.59 | 17.90 | 19.11 | 60.36 | 131.12 | 198.08 | 261.22 |
Free Cash Flow |
(2.29) | (2.82) | (4.11) | (4.65) | (4.74) | (4.27) | (6.40) | (6.44) | 1.48 | (8.80) |
Working Capital |
7.08 | 5.69 | 8.78 | 12.58 | 17.30 | 11.43 | 9.67 | (0.41) | 3.94 | 6.47 |
Capital Expenditures |
— | — | — | — | — | — | 0.00 | 0.02 | (0.01) | (0.02) |
Net Current Asset Value |
7.08 | 5.69 | 8.78 | 12.58 | 17.30 | 11.41 | 6.76 | (3.32) | 1.02 | 3.53 |
EV/EBIT |
1.08 | 0.00 | 0.53 | 1.13 | 0.67 | 0.00 | 0.40 | — | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.12) | 0.00 | 0.00 | 0.01 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
— | — | — | 0.00 | 0.00 | 0.00 | 4,138.63 | 3.16 | 0.86 | 13.70 |
Cash ROIC |
(14.97%) | (23.15%) | (21.91%) | (17.37%) | (12.93%) | (17.97%) | (23.19%) | (61.05%) | 7.46% | (43.40%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 1.84 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.17 | 0.03 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | — | — | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1,839.73 | 10,096.66 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | — | — | 0.00 | 0.00 | 0.00 |
Average Receivables |
— | — | — | — | — | — | — | — | — | 1.63 |
Average Payables |
0.27 | 0.26 | 0.26 | 0.32 | 0.34 | 0.63 | 0.93 | 0.86 | 0.90 | 1.40 |
Average Assets |
7.63 | 8.75 | 12.66 | 17.27 | 16.50 | 17.36 | 17.99 | 16.80 | 20.07 | 18.94 |
Average Common Equity |
6.70 | 7.90 | 11.72 | 16.02 | 15.30 | 14.71 | 13.56 | 12.10 | 15.23 | 11.39 |
Columns are period end dates